| HUMAN-TRIAL | evidence | Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial. | Mounjaro | Weight & fat loss · human-observational | 2026-12-01 |
| HUMAN-TRIAL | evidence | Association of GLP-1 receptor agonists with alcohol use disorder-related and substance use disorder-related hospital admissions during treatment and after discontinuation: a Swedish register-based within-individual observational study. | Tirzepatide | Glycemic control · human-observational | 2026-08-01 |
| HUMAN-TRIAL | evidence | Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial. | Tirzepatide | Weight & fat loss · human-rct | 2026-08-01 |
| HUMAN-TRIAL | evidence | Effect of Tirzepatide on Health-Related Quality of Life in Japanese Patients With Obesity Disease: Patient-Reported Outcomes From the SURMOUNT-J Study. | Tirzepatide | Weight & fat loss · human-rct | 2026-08-01 |
| HUMAN-TRIAL | evidence | Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO). | Tirzepatide | Glycemic control · human-rct · n = 206 | 2026-07-10 |
| HUMAN-TRIAL | evidence | Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial. | Tirzepatide | Weight & fat loss · human-rct | 2026-07-01 |
| HUMAN-TRIAL | evidence | Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. | Tirzepatide | Weight & fat loss · human-rct | 2026-07-01 |
| HUMAN-TRIAL | evidence | Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. | Tirzepatide | Weight & fat loss · human-rct | 2026-07-01 |
| HUMAN-TRIAL | evidence | Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes : A Randomized Clinical Trial. | Tirzepatide | Glycemic control · human-rct | 2026-07-01 |
| HUMAN-TRIAL | evidence | A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. | Tirzepatide | Glycemic control · human-rct | 2026-07-01 |
| HUMAN-TRIAL | evidence | Six-Month Real-World Effectiveness, Persistence and Safety of Low-to-Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study. | Tirzepatide | Weight & fat loss · human-observational | 2026-07-01 |
| HUMAN-TRIAL | evidence | Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. | Tirzepatide | Weight & fat loss · human-rct | 2026-07-01 |
| HUMAN-TRIAL | evidence | Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety. | Tirzepatide | Weight & fat loss · human-observational · n = 34 | 2026-07-01 |
| HUMAN-TRIAL | evidence | Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. | Tirzepatide | Weight & fat loss · human-rct | 2026-06-06 |
| HUMAN-TRIAL | evidence | Effects of testosterone undecanoate as add-on therapy in obese hypogonadal men that are late responders to tirzepatide: a pilot study. | Tirzepatide | Weight & fat loss · human-observational · n = 10 | 2026-06-01 |
| HUMAN-TRIAL | evidence | Preoperative GLP-1 Receptor Agonists and Thromboinflammatory Markers in Patients Undergoing Abdominoplasty: A Prospective Monocentric Study. | Tirzepatide | Weight & fat loss · human-observational | 2026-06-01 |
| HUMAN-TRIAL | evidence | Real-World Clinical Evidence of Tirzepatide for Metabolic Abnormalities in Subjects With Type 2 Diabetes: The Multicenter Retrospective Observational Hokkaido-TZP Study. | Tirzepatide | Glycemic control · human-observational | 2026-06-01 |
| HUMAN-TRIAL | evidence | Shifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc analysis of SURMOUNT-1. | Tirzepatide | Weight & fat loss · human-rct | 2026-06-01 |
| HUMAN-TRIAL | evidence | Glucagon-Like Peptide-1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients. | Tirzepatide | Sleep quality · human-observational · n = 384 | 2026-06-01 |
| HUMAN-TRIAL | evidence | Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on cardiovascular-kidney-metabolic stage progression: a real-world cohort study. | Tirzepatide | Lipid & cardiovascular markers · human-observational · n = 897182 | 2026-06-01 |
| HUMAN-TRIAL | evidence | Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial. | Tirzepatide | Glycemic control · human-rct | 2026-06-01 |
| HUMAN-TRIAL | evidence | Glucagon-like peptide-1 receptor agonists in patients with heart failure with reduced ejection fraction. | Tirzepatide | Lipid & cardiovascular markers · human-observational · n = 127021 | 2026-05-05 |
| HUMAN-TRIAL | evidence | Short-term effect of tirzepatide on serum calcitonin in adults with obesity. | Tirzepatide | Weight & fat loss · human-observational | 2026-05-04 |
| HUMAN-TRIAL | evidence | Tirzepatide versus semaglutide for the prevention of mild cognitive impairment, dementia, and Alzheimer's disease in type 2 diabetes: A real-world, retrospective cohort study. | Tirzepatide | Cognition & memory · human-observational · n = 335077 | 2026-05-01 |
| HUMAN-TRIAL | evidence | Genetic predictors of GLP1 receptor agonist weight loss and side effects. | Tirzepatide | Weight & fat loss · human-observational · n = 27885 | 2026-05-01 |
| HUMAN-TRIAL | evidence | Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting. | Tirzepatide | Glycemic control · human-rct | 2026-05-01 |
| HUMAN-TRIAL | evidence | Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial. | Tirzepatide | Glycemic control · human-rct | 2026-05-01 |
| HUMAN-TRIAL | evidence | Comparative real-world outcomes of tirzepatide vs semaglutide in patients with obesity and type2 diabetes: A retrospective propensity-matched cohort study. | Tirzepatide | Glycemic control · human-observational | 2026-05-01 |
| HUMAN-TRIAL | evidence | A retrospective audit of weight loss and health outcomes following bariatric surgery at a tertiary public hospital. | Tirzepatide | Weight & fat loss · human-observational · n = 203 | 2026-05-01 |
| HUMAN-TRIAL | evidence | Muscle atrophy associated with glucagon-like Peptide-1 receptor agonists: A population-based observational study. | Tirzepatide | human-observational | 2026-05-01 |
| HUMAN-TRIAL | evidence | Toward Precision Obesity Pharmacotherapy: Using the Eating Behavior Phenotype Scale (EFCA) in Real-World Clinical Practice. | Tirzepatide | Weight & fat loss · human-observational | 2026-04-30 |
| HUMAN-TRIAL | evidence | Real-world prescribing patterns and early weight and blood pressure outcomes of GLP-1-based therapies: a retrospective observational study in the United Arab Emirates. | Tirzepatide | Weight & fat loss · human-observational | 2026-04-12 |
| HUMAN-TRIAL | evidence | Varying Hypopnea Definitions and Treatment Eligibility in Obstructive Sleep Apnea. | Tirzepatide | Sleep quality · human-observational · n = 2057 | 2026-04-02 |
| HUMAN-TRIAL | evidence | ARD-101, a gut-restricted TAS2R agonist, reduces hunger in adults and promotes weight loss in DIO mice with DPP-4 inhibition. | Tirzepatide | Weight & fat loss · human-rct | 2026-04-01 |
| HUMAN-TRIAL | evidence | A treat-to-target approach for obesity management: A post hoc analysis of the SURMOUNT-5 trial. | Tirzepatide | Weight & fat loss · human-observational | 2026-04-01 |
| HUMAN-TRIAL | evidence | Post hoc analysis of SURMOUNT-J: tirzepatide versus placebo and predicted 10-year cardiovascular disease risk in Japanese adults with obesity disease. | Tirzepatide | human-rct | 2026-04-01 |
| HUMAN-TRIAL | evidence | Effectiveness and adherence in a tirzepatide-supported digital weight-loss programme in Australia: A real-world observational study. | Tirzepatide | Weight & fat loss · human-observational | 2026-04-01 |
| HUMAN-TRIAL | evidence | Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH. | Tirzepatide | Glycemic control · human-rct | 2026-03-30 |
| HUMAN-TRIAL | evidence | Bispecific GLP-1/GLP-2 agonism in advanced type 2 diabetes: preclinical characterization and a randomized, double-blind, placebo-controlled phase I trial. | Tirzepatide | Glycemic control · human-rct | 2026-03-24 |
| HUMAN-TRIAL | evidence | Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials. | Tirzepatide | Weight & fat loss · human-rct | 2026-03-02 |
| HUMAN-TRIAL | evidence | Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT-1 Trial. | Tirzepatide | Weight & fat loss · human-rct | 2026-03-01 |
| HUMAN-TRIAL | evidence | Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT. | Tirzepatide | Weight & fat loss · human-rct | 2026-03-01 |
| HUMAN-TRIAL | evidence | A real-world study of tirzepatide for weight loss in adults without diabetes mellitus. | Tirzepatide | Weight & fat loss · human-observational | 2026-03-01 |
| HUMAN-TRIAL | evidence | Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER). | Tirzepatide | Weight & fat loss · human-observational | 2026-03-01 |
| HUMAN-TRIAL | evidence | [SURPASS CVOT : cardiovascular benefits with tirzepatide versus dulaglutide in type 2 diabetes]. | Tirzepatide | Glycemic control · human-observational | 2026-03-01 |
| HUMAN-TRIAL | evidence | Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial. | Tirzepatide | Weight & fat loss · human-rct | 2026-03-01 |
| HUMAN-TRIAL | evidence | GLP-1 receptor agonists reduce body mass index and total daily insulin dose in youth with type 1 diabetes: a retrospective cohort study. | Tirzepatide | Glycemic control · human-observational | 2026-02-24 |
| HUMAN-TRIAL | evidence | Semaglutide vs tirzepatide in patients with obesity and HFpEF: a report from a global federated research network. | Tirzepatide | human-observational | 2026-02-03 |
| HUMAN-TRIAL | evidence | Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. | Tirzepatide | Weight & fat loss · human-rct | 2026-02-01 |
| HUMAN-TRIAL | evidence | Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT-J trial. | Tirzepatide | Weight & fat loss · human-rct | 2026-02-01 |